Tetrapeptide having effect of inhibiting VEGF-induced angiogenesis and use thereof
US9969771B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 28, 2016 |
| Grant date | May 15, 2018 |
| Priority date | — |
| Expiry date | Jul 28, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are a tetrapeptide for inhibiting VEGF-induced angiogenesis and a use thereof, and particularly, provided is a peptide having the amino acid sequence of R-X1-X2-E (wherein X1 is leucine (L), isoleucine (I) or valine (V), and X2 is tyrosine (Y) or phenylalanine (F)) for inhibiting angiogenesis, or preventing, improving or treating cancer. This research was supported by grants from the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea, in 2011 and 2013 [NRF-2011-0028790 and 2013M3A9B6046563]. The tetrapeptide may effectively inhibit VEGF-induced angiogenesis or growth of cancer cells without a risk of side effects, and therefore may be expected to exhibit an excellent anticancer effect.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.